CT45A1

Summary

CT45A1 (cancer/testis antigen family 45 member A1, HGNC:33267) is a protein-coding gene on chromosome Xq26.3, encoding Cancer/testis antigen family 45 member A1 (Q5HYN5). It is a selective cancer dependency (DepMap: 60.0% of cell lines).

Located in nucleus.

Source: NCBI Gene 541466 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 12 total
• Cancer dependency (DepMap): dependent in 60.0% of screened cell lines
• MANE Select transcript: NM_001017417

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:33267
Approved symbol	CT45A1
Name	cancer/testis antigen family 45 member A1
Location	Xq26.3
Locus type	gene with protein product
Status	Approved
Aliases	CT45-1, CT45.1
Ensembl gene	ENSG00000268940
Ensembl biotype	protein_coding
OMIM	300648
Entrez	541466

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 2 protein_coding

ENST00000594117, ENST00000594565

RefSeq mRNA: 1 — MANE Select: NM_001017417 NM_001017417

CCDS: CCDS48174

Canonical transcript exons

ENST00000594565 — 5 exons

Exon	Start	End
ENSE00003010257	135721658	135721751
ENSE00003035483	135721028	135721276
ENSE00003039235	135718935	135719109
ENSE00003179741	135713639	135713690
ENSE00003918962	135722976	135723228

Expression profiles

Bgee: expression breadth broad, 48 present calls, max score 90.94.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.0502 / max 13.7760, expressed in 23 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
209824	0.0502	23

Top tissues by expression

121 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	90.94	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	88.25	gold quality
right testis	UBERON:0004534	73.53	gold quality
testis	UBERON:0000473	72.74	gold quality
left testis	UBERON:0004533	71.78	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	45.50	gold quality
Ammon’s horn	UBERON:0001954	45.07	gold quality
hypothalamus	UBERON:0001898	44.16	gold quality
caudate nucleus	UBERON:0001873	41.85	gold quality
substantia nigra	UBERON:0002038	41.07	gold quality
nucleus accumbens	UBERON:0001882	40.85	gold quality
amygdala	UBERON:0001876	38.47	gold quality
temporal lobe	UBERON:0001871	38.36	gold quality
granulocyte	CL:0000094	37.45	gold quality
colonic epithelium	UBERON:0000397	37.20	gold quality
prefrontal cortex	UBERON:0000451	36.86	gold quality
ventricular zone	UBERON:0003053	36.48	gold quality
cortical plate	UBERON:0005343	36.47	gold quality
bone marrow cell	CL:0002092	36.16	gold quality
ganglionic eminence	UBERON:0004023	35.49	gold quality
putamen	UBERON:0001874	35.45	gold quality
cerebral cortex	UBERON:0000956	35.36	gold quality
anterior cingulate cortex	UBERON:0009835	35.28	gold quality
sural nerve	UBERON:0015488	34.93	gold quality
brain	UBERON:0000955	34.45	gold quality
frontal cortex	UBERON:0001870	34.01	gold quality
primary visual cortex	UBERON:0002436	33.54	silver quality
skeletal muscle tissue	UBERON:0001134	33.38	gold quality
Brodmann (1909) area 9	UBERON:0013540	33.21	gold quality
ectocervix	UBERON:0012249	32.85	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.47

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

18 targeting CT45A1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-450A-1-3P	100.00	69.33	1837
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-4455	100.00	65.48	1587
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-6845-3P	99.94	66.88	1439
HSA-MIR-3671	99.90	73.04	3897
HSA-MIR-3133	99.81	70.92	3506
HSA-MIR-4668-5P	99.79	70.58	3782
HSA-MIR-586	99.65	70.40	2051
HSA-MIR-5006-5P	98.79	66.92	1246
HSA-MIR-5572	98.55	65.84	970
HSA-MIR-6819-5P	97.96	66.59	1071
HSA-MIR-3151-3P	97.80	66.16	479
HSA-MIR-6737-5P	97.75	66.54	1044
HSA-MIR-6812-5P	97.56	65.39	1059
HSA-MIR-3674	97.01	68.86	1171
HSA-MIR-6747-5P	96.17	64.99	743

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 60.0% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 9)

• Over-expression of CT45 is associated with cancer. (PMID:19296537)
• Hodgkin lymphoma has the highest CT45 expression among all malignancies tested, in diffuse large B-cell lymphomas it is similar to that seen in epithelial cancers, and not present in low-grade non-Hodgkin B-cell lymphomas. (PMID:20133697)
• CT45A1 functions as a novel proto-oncogene to trigger oncogenesis and metastasis. (PMID:24901056)
• These data verify CT45 expression and promoter hypomethylation as possible prognostic biomarkers, and suggest CT45 as an immunological or therapeutic target in Epithelial ovarian cancer (PMID:26098711)
• Following CT45A1 silencing, the expressions of Bcl2, survivin, MMP2, MMP9, pERK1/2 and pCREB were downregulated and the expression of Bax was upregulated. (PMID:28901509)
• YBX2 and cancer testis antigen 45 contribute to stemness, chemoresistance and a high degree of malignancy in human endometrial cancer. (PMID:33602962)
• CT45A1 promotes the metastasis of osteosarcoma cells in vitro and in vivo through beta-catenin. (PMID:34172717)
• Uev1A promotes breast cancer cell migration by up-regulating CT45A expression via the AKT pathway. (PMID:34503444)
• Cancer/testis-45A1 promotes cervical cancer cell tumorigenesis and drug resistance by activating oncogenic SRC and downstream signaling pathways. (PMID:37924456)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
mus_musculus	Ct45a	ENSMUSG00000064016
rattus_norvegicus	Ct45a9	ENSRNOG00000048059
drosophila_melanogaster	IntS6	FBGN0261383
caenorhabditis_elegans		WBGENE00000994

Paralogs (11): INTS6 (ENSG00000102786), INTS6L (ENSG00000165359), SAGE1 (ENSG00000181433), CT45A5 (ENSG00000228836), CT45A3 (ENSG00000269096), CT45A10 (ENSG00000269586), CT45A9 (ENSG00000270946), CT45A2 (ENSG00000271449), CT45A7 (ENSG00000273696), CT45A8 (ENSG00000278085), CT45A6 (ENSG00000278289)

Protein

Protein identifiers

Cancer/testis antigen family 45 member A1 — Q5HYN5 (reviewed: Q5HYN5)

Alternative names: Cancer/testis antigen 45-1, Cancer/testis antigen 45A1

All UniProt accessions (1): Q5HYN5

UniProt curated annotations — full annotation on UniProt →

Subcellular location. Nucleus.

Tissue specificity. Testis specific. Expressed in cancer cell lines.

Similarity. Belongs to the CT45 family.

RefSeq proteins (1): NP_001017417* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR029307	INT_SG_DDX_CT_C	Domain
IPR051113	Integrator_subunit6	Family

Pfam: PF15300

UniProt features (4 total): region of interest 2, chain 1, compositionally biased region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q5HYN5-F1	69.95	0.23

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 8 (showing top): chrXq26, CHAMP1_TARGET_GENES, ZNF512_TARGET_GENES, MIR3671, MIR450A_1_3P, CC2D1A_TARGET_GENES, HE_LIM_SUN_FETAL_LUNG_C0_MYOFIBROBLAST_1_CELL, HE_LIM_SUN_FETAL_LUNG_C0_MYOFIBROBLAST_2_CELL

GO Biological Process (0):

GO Molecular Function (1): protein binding (GO:0005515)

GO Cellular Component (1): nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

306 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CT45A1	MAGEC1	O60732	649
CT45A1	SPANXA1	Q9NS26	608
CT45A1	CT47A11	Q5JQC4	602
CT45A1	MAGEC2	Q9UBF1	584
CT45A1	GAGE2A	Q6NT46	584
CT45A1	XAGE1B	Q9HD64	582
CT45A1	NXF2B	Q9GZY0	570
CT45A1	CTAG1A	P78358	541
CT45A1	CT55	Q8WUE5	525
CT45A1	MAGEA4	P43358	516
CT45A1	ACTL8	Q9H568	507
CT45A1	PASD1	Q8IV76	506
CT45A1	CSAG2	Q9Y5P2	506
CT45A1	MAGEA10	P43363	482
CT45A1	CTAG2	O75638	479
CT45A1	A0A1W2PQG5	A0A1W2PQG5	479

IntAct

55 interactions, top by confidence:

A	B	Type	Score
CT45A1	MAB21L3	psi-mi:“MI:0915”(physical association)	0.560
CT45A1	NTAQ1	psi-mi:“MI:0915”(physical association)	0.560
RNF151	CT45A1	psi-mi:“MI:0915”(physical association)	0.560
CT45A1	MMTAG2	psi-mi:“MI:0915”(physical association)	0.560
CKS1B	CT45A1	psi-mi:“MI:0915”(physical association)	0.560
FGF12	CT45A1	psi-mi:“MI:0915”(physical association)	0.560
CT45A1	SDCBP2	psi-mi:“MI:0915”(physical association)	0.560
CDC37	CT45A1	psi-mi:“MI:0915”(physical association)	0.560
CT45A1	SREK1IP1	psi-mi:“MI:0915”(physical association)	0.560
PRPF40A	CT45A1	psi-mi:“MI:0915”(physical association)	0.560
RPL22	CT45A1	psi-mi:“MI:0915”(physical association)	0.560
CT45A1	FAM133A	psi-mi:“MI:0915”(physical association)	0.560
GAS8	CT45A1	psi-mi:“MI:0915”(physical association)	0.560
CT45A10	CT45A1	psi-mi:“MI:0915”(physical association)	0.560
SDCBP	CT45A1	psi-mi:“MI:0915”(physical association)	0.560
BCL2A1	CT45A1	psi-mi:“MI:0915”(physical association)	0.560
CSNK2A1	CT45A1	psi-mi:“MI:0915”(physical association)	0.560
CT45A1	NKAPD1	psi-mi:“MI:0915”(physical association)	0.560
MAB21L3	CT45A1	psi-mi:“MI:0915”(physical association)	0.000
NTAQ1	CT45A1	psi-mi:“MI:0915”(physical association)	0.000
RNF151	CT45A1	psi-mi:“MI:0915”(physical association)	0.000
MMTAG2	CT45A1	psi-mi:“MI:0915”(physical association)	0.000
CKS1B	CT45A1	psi-mi:“MI:0915”(physical association)	0.000
CSNK2A1	CT45A1	psi-mi:“MI:0915”(physical association)	0.000
NKAPD1	CT45A1	psi-mi:“MI:0915”(physical association)	0.000
FAM133A	CT45A1	psi-mi:“MI:0915”(physical association)	0.000
GAS8	CT45A1	psi-mi:“MI:0915”(physical association)	0.000
CT45A10	CT45A1	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (28): CT45A1 (Affinity Capture-MS), CT45A1 (Affinity Capture-MS), CT45A1 (Affinity Capture-MS), CT45A1 (Affinity Capture-MS), CT45A1 (Two-hybrid), CT45A1 (Two-hybrid), CT45A1 (Two-hybrid), CT45A1 (Two-hybrid), CT45A1 (Two-hybrid), CT45A1 (Two-hybrid), CT45A1 (Two-hybrid), CT45A1 (Two-hybrid), CT45A1 (Two-hybrid), CT45A1 (Two-hybrid), CT45A1 (Two-hybrid)

ESM2 similar proteins: A8MQG7, B1Q3J6, B4R1Z3, E7BQV0, F4K493, O23273, O54917, O75461, P0DMU7, P0DMU8, P0DMU9, P0DMV0, P0DMV1, P0DMV2, P46640, Q08AX9, Q08DY6, Q09394, Q0V9S3, Q12830, Q1LVQ2, Q24K09, Q5DJT8, Q5HYN5, Q5ICL9, Q68FF0, Q6NSI8, Q6PI47, Q6Z8M8, Q700C2, Q7X9V2, Q7XHR2, Q8AXQ3, Q8BFX3, Q8L746, Q8LF97, Q8NHU0, Q8RY95, Q8VZN4, Q8WML3

Diamond homologs: A6NJ88, P0DMU7, P0DMU8, P0DMU9, P0DMV0, P0DMV1, P0DMV2, Q2TAF4, Q5DJT8, Q5HYN5, Q5JSJ4, Q5U4W6, Q6PCM2, Q7SYD9, Q8BND4, Q8NHU0, Q9NXZ1, Q9UL03, Q54Z23, Q9W485

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

12 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	6
Likely benign	4
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

598 predictions. Top by Δscore:

Variant	Effect	Δscore
X:135719108:GA:G	donor_gain	1.0000
X:135721027:GA:G	acceptor_gain	1.0000
X:135721275:AA:A	donor_gain	1.0000
X:135721276:AG:A	donor_loss	1.0000
X:135721277:G:GG	donor_gain	1.0000
X:135721277:GTAA:G	donor_loss	1.0000
X:135721278:T:G	donor_loss	1.0000
X:135721647:A:AG	acceptor_gain	1.0000
X:135721648:A:AG	acceptor_gain	1.0000
X:135721649:C:G	acceptor_gain	1.0000
X:135721650:A:AG	acceptor_gain	1.0000
X:135721651:T:G	acceptor_gain	1.0000
X:135721653:TTCA:T	acceptor_loss	1.0000
X:135721654:TCAGA:T	acceptor_loss	1.0000
X:135721656:A:AG	acceptor_gain	1.0000
X:135721656:AGAA:A	acceptor_loss	1.0000
X:135721657:G:GA	acceptor_gain	1.0000
X:135721657:GA:G	acceptor_gain	1.0000
X:135721657:GAA:G	acceptor_gain	1.0000
X:135721657:GAAT:G	acceptor_gain	1.0000
X:135721657:GAATA:G	acceptor_gain	1.0000
X:135721713:G:GT	donor_gain	1.0000
X:135721741:G:GT	donor_gain	1.0000
X:135721747:GCAAG:G	donor_gain	1.0000
X:135721752:G:GA	donor_loss	1.0000
X:135721752:G:GG	donor_gain	1.0000
X:135718929:TTTCA:T	acceptor_loss	0.9900
X:135718930:TTCAG:T	acceptor_loss	0.9900
X:135718931:TCAGG:T	acceptor_loss	0.9900
X:135718932:CA:C	acceptor_loss	0.9900

AlphaMissense

1259 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
X:135721744:G:C	A169P	0.880
X:135718986:T:C	F16L	0.856
X:135718988:T:A	F16L	0.856
X:135718988:T:G	F16L	0.856
X:135721672:T:C	F145L	0.850
X:135721674:C:A	F145L	0.850
X:135721674:C:G	F145L	0.850
X:135721239:A:C	K127N	0.831
X:135721239:A:T	K127N	0.831
X:135721723:T:C	F162L	0.823
X:135721725:T:A	F162L	0.823
X:135721725:T:G	F162L	0.823
X:135721696:G:A	G153R	0.816
X:135721696:G:C	G153R	0.816
X:135721682:T:A	L148H	0.759
X:135721227:T:A	N123K	0.758
X:135721227:T:G	N123K	0.758
X:135721720:T:C	F161L	0.744
X:135721722:T:A	F161L	0.744
X:135721722:T:G	F161L	0.744
X:135719030:G:C	R30S	0.730
X:135719030:G:T	R30S	0.730
X:135721721:T:C	F161S	0.728
X:135722992:T:C	F177L	0.726
X:135722994:T:A	F177L	0.726
X:135722994:T:G	F177L	0.726
X:135721247:T:C	L130S	0.715
X:135723005:T:C	L181P	0.710
X:135723005:T:A	L181H	0.707
X:135719010:A:C	S24R	0.703

dbSNP variants (sampled 300 via entrez): RS1043128918 (X:135708630 A>G), RS11095646 (X:135711768 A>G), RS111309217 (X:135712302 C>T), RS111642789 (X:135711750 T>C), RS111680896 (X:135713671 G>A), RS111729607 (X:135714061 C>T), RS112090346 (X:135712719 C>T), RS112177643 (X:135712175 C>A,T), RS112237074 (X:135709789 T>A), RS112802936 (X:135714076 G>C,T), RS113132610 (X:135715239 T>A), RS113232362 (X:135711855 T>C,G), RS113495738 (X:135713448 T>C), RS113662171 (X:135709770 G>A,T), RS115311758 (X:135713093 G>A,C,T)

Disease associations

OMIM: gene MIM:300648 | disease phenotypes:

GenCC curated gene-disease

Mondo (2): primary ovarian failure (MONDO:0005387), male infertility (MONDO:0005372)

Orphanet (1): NON RARE IN EUROPE: Primary ovarian failure (Orphanet:619)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D007248	Infertility, Male	C12.100.500.430; C12.100.750.700; C12.200.294.430
D016649	Primary Ovarian Insufficiency	C12.050.351.500.056.630.750; C12.100.250.056.630.750; C19.391.630.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

15 total (human), top 15 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
propionaldehyde	increases expression	1
butyraldehyde	increases expression	1
gallium arsenide	increases expression	1
pentanal	increases expression	1
CGP 52608	increases reaction, affects binding	1
bisphenol S	affects cotreatment, decreases methylation	1
Fulvestrant	affects cotreatment, decreases methylation	1
Aldehydes	increases expression	1
Benzo(a)pyrene	increases methylation	1
Tretinoin	decreases expression	1
Valproic Acid	increases methylation	1
Asbestos, Serpentine	increases expression	1
Cadmium Chloride	increases expression	1
Okadaic Acid	decreases expression	1
Copper Sulfate	affects expression	1

Clinical trials (associated diseases)

199 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00417066	PHASE4	COMPLETED	Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders
NCT00732693	PHASE4	COMPLETED	Evaluation of Physiologic and Standard Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure
NCT00837616	PHASE4	COMPLETED	Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism
NCT01853501	PHASE4	UNKNOWN	Effects of ADSC Therapy in Women With POF
NCT02783937	PHASE4	COMPLETED	Filgrastim for Premature Ovarian Insufficiency
NCT03535480	PHASE4	UNKNOWN	Autologous Bone Marrow Stem Cell Ovarian Transplantation to Restore Ovarian Function in Premature Ovarian Failure
NCT02202382	PHASE4	COMPLETED	Effects of Korean Red Ginseng on Male Infertility
NCT02204826	PHASE4	COMPLETED	Effects of Korean Red Ginseng on Semen Parameters in Male Infertility Patients: a Randomized, Placebo-controlled, Double-blind Clinical Study
NCT03802864	PHASE4	COMPLETED	Post-operative Pain Control of Testicular Sperm Extraction Using Liposomal Bupivacaine
NCT06100432	PHASE4	ACTIVE_NOT_RECRUITING	Effect of Eurycoma Longifolia (DLBS5055) and Multivitamins (Vitamin C+Vitamin E+ β-carotene) for Infertile Males
NCT07523022	PHASE4	ENROLLING_BY_INVITATION	Comparison of the Effect of Gonadotropin and Clomiphene Citrate Treatment on Sperm Parameters and the Outcome of Assisted Reproductive Procedures in Subfertile Men Based on the APHRODITE Groups
NCT00140998	PHASE3	COMPLETED	Estrogen Treatment (Oral vs. Patches) in Turner Syndrome
NCT00975117	PHASE3	COMPLETED	Spermotrend in the Treatment of Male Infertility
NCT01407432	PHASE3	COMPLETED	Impact of Folates in the Care of the Male Infertility
NCT01895816	PHASE3	COMPLETED	Herbal Tonic Fertile Supplement(ZO2C5)
NCT02605070	PHASE3	TERMINATED	Pilot Study on the Effects of FSH Treatment on the Epigenetic Characteristics of Spermatozoa in Infertile Patients With Severe Oligozoospermia
NCT07402759	PHASE3	ACTIVE_NOT_RECRUITING	Impact of tdrd9 Gene Mutations in the Therapeutic Response to L-carnitine in Oligoasthenozoospermic Men
NCT00001951	PHASE2	COMPLETED	Hormone Replacement in Young Women With Premature Ovarian Failure
NCT00370019	PHASE2	WITHDRAWN	Effects of an Estrogen Replacement Therapy Skin Patch on Ovulation in Women With Premature Ovarian Failure
NCT00429494	PHASE2	COMPLETED	GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients
NCT03816852	PHASE2	SUSPENDED	The Safety and Efficiency Study of Mesenchymal Stem Cell (19#iSCLife®-POI) in Premature Ovarian Insufficiency
NCT04536467	PHASE2	UNKNOWN	Prevention of Chemotherapy-Induced Ovarian Failure With Goserelin in Premenopausal Lymphoma Patients
NCT06117982	PHASE2	COMPLETED	The Impact of Granulocyte Colony Stimulating Factor on Premature Ovarian Insufficiency
NCT01880086	PHASE2	COMPLETED	Clomiphene Citrate for the Treatment of Low Testosterone Associated With Chronic Opioid Pain Medication Administration
NCT02061384	PHASE2	COMPLETED	RA-2 13-cis Retinoic Acid (Isotretinoin)
NCT02421887	PHASE2	COMPLETED	Males, Antioxidants, and Infertility Trial
NCT05200663	PHASE2	UNKNOWN	Efficacy Comparison of Tamoxifen and Tamoxifen With Antioxidants on Semen Quality of Male With Idiopathic Infertility
NCT05290558	PHASE2	ACTIVE_NOT_RECRUITING	The Therapeutic Effects of Bu Shen Yi Jing Pill on Semen Quality in Sub Fertile Males: a Randomized Controlled Trial
NCT06091969	PHASE2	NOT_YET_RECRUITING	Supplementation for Male Subfertility
NCT02912104	PHASE1	COMPLETED	A Therapeutic Trial of Human Amniotic Epithelial Cells Transplantation for Primary Ovarian Failure
NCT03178695	PHASE1	COMPLETED	Inovium Ovarian Rejuvenation Trials
NCT04815213	PHASE1	ACTIVE_NOT_RECRUITING	The Use of Expandeded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans
NCT05138367	PHASE1	COMPLETED	Effects of UCA-PSCs in Women With POF
NCT06132542	PHASE1	UNKNOWN	Autologous ADMSC Transplantation in Patients With POI
NCT01595308	PHASE1	COMPLETED	A Pilot Study to Evaluate the Effect of Pomegranate Juice on Semen Parameters in Healthy Male Volunteers
NCT02122211	PHASE1	COMPLETED	Choline Dehydrogenase and Sperm Function: Effects of Betaine
NCT02575924	PHASE1	UNKNOWN	Influence of Culture Media on Clinical Outcomes in Poor Responders or Severe Male Infertility
NCT00948857	PHASE2/PHASE3	TERMINATED	Dehydroepiandrosterone (DHEA) Treatment and Premature Ovarian Failure (POF)
NCT04031456	PHASE2/PHASE3	RECRUITING	Autologous PRP Infusion May Restore Ovarian Function and May Promote Folliculogenesis in POI Patients
NCT02043743	PHASE1/PHASE2	UNKNOWN	Autologous Stem Cells Transplantation in Patients With Idiopathic and Drug Induced Premature Ovarian Failure